



ASSURING THE SAFETY, QUALITY & EFFICACY  
OF VETERINARY MEDICINES

**Copyright notice**

The information below was supplied in response to an Access to Information (ATI) request. It is the copyright of the Veterinary Medicines Directorate. You are free to use it for your own purposes, including for private study and non-commercial research, and for any other purpose authorised by an exception in current copyright law. Documents (except photographs or logos) can be also used in the UK without requiring permission for the purposes of news reporting. Any other re-use, for example commercial publication, would require the permission of the copyright holder.

**ATI 304**

**Request**

**From:** [Redacted under section 40 of the FOIA]

**Sent:** 25 June 2014

**Subject:** Request for information

Dear Mme/Sir,

May I have free access to information on ecotox data for preparing phase 1 and 2 evaluation of florfenicol applied to chickens (20 mg/kg bw) for 5 days?

**VMD Reply**

**Sent:** 27 June 2014

**To:** [Redacted under section 40 of the FOIA]

**Subject:** Request for information

**Your Request**

Thank you for your email below dated 25 June 2014.

We are dealing with your request under the Freedom of Information Act 2000 (FOIA).

You asked for all information on ecotox data for preparing phase 1 and 2 evaluation of florfenicol applied to chickens (20 mg/kg bw) for 5 days?

**Our Reply**

We fully recognise and respect the obligations imposed by the FOIA on the VMD to act in a manner that is transparent and open in the public interest. However the very real harm likely to ensue from the disclosure of the information you request warrants the balance to be taken in favour of non-disclosure.

Through the marketing authorisation system the VMD receives information from commercial entities that constitutes trade secrets and information protected by patent, the publication of which would create significant commercial harm to the manufacturer. The commercial entities are required by law to provide the information and are put to great expense to generate it. In this case, the information you request could be used by other manufacturers to formulate, develop or market products that would compete with these products.

Further, the market as a whole benefits from establishing and upholding a robust process for marketing authorisations; this in turn requires appropriate protection of confidentiality, and the honouring of expectations of confidentiality.

We consider such factors weigh against the public interest in disclosing the information in question. In these circumstances, we consider that sections 41 and 43 of the FOIA apply to this request and that it would not be in the public interest for the VMD to release this information. Publishing such information could undermine the veterinary pharmaceuticals industry's trust in the regulatory process as well as the companies' commercial position. This could lead to companies becoming unwilling to place product on the UK market, which would have a detrimental impact on animal welfare.

You may want to look at the VMD's website via the link below to see what kind of information we do release, particularly those related to end-point data.

[http://webarchive.nationalarchives.gov.uk/20140304235049/http://www.vmd.defra.gov.uk/business/ati\\_disclosure.aspx](http://webarchive.nationalarchives.gov.uk/20140304235049/http://www.vmd.defra.gov.uk/business/ati_disclosure.aspx)

In relation to the end point data we release you should note that such end point values could not be used as a substitute for Environmental Risk Assessment (ERA) data. The document "Guidance on the Assessment of environmental risks of veterinary medicinal products" published in the Notice to Applicants, Volume 6C, June 2009 in respect of the assessment of environmental risks of veterinary medical products, sets out what data can be accepted when preparing an ERA, as follows:

"Published data provided must be of a quality to enable an assessment of the risks to the environment which is equivalent to that enabled by specifically generated studies in accordance with agreed guidelines, i.e. they can only be used to substitute studies, if the publication contains a sufficient amount of data and sufficient details on the design and conduct of the study to allow a full and independent assessment. Therefore, the provision of only end point values or a published summary of an assessment is not sufficient to substitute ERA data."

### **Our Service**

If you are unhappy with the service you have received in relation to your request and wish to make a complaint, you may request an internal review within two calendar months of the date of this e-mail. If you would like to request an internal review please write to [Redacted under section 40 of the FOIA] at the VMD via [ati@vmd.defra.gsi.gov.uk](mailto:ati@vmd.defra.gsi.gov.uk). If you are not content with the outcome of the internal review you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be

contacted at: Information Commissioner's Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF